Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00867217 · ClinicalTrials.gov registry record · Phase 2
Vitamin D3 for Aromatase Inhibitor Induced Arthralgias
A Phase 2 study, sponsored by Qamar Khan.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT00867217: Completed Phase 2 study, sponsored by Qamar Khan.
NCT00867217 is a Phase 2 study that has completed, run by Qamar Khan. The registered enrollment target is 160 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00867217, a Phase 2 study, has completed, sponsored by Qamar Khan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
The primary purpose is to determine if high dose vitamin D3 reduces the incidence of musculoskeletal symptoms associated with the aromatase inhibitor letrozole in women with early stage breast cancer and low serum vitamin D levels.
Primary Outcome
Worsening of Musculoskeletal Symptoms (MS) is defined as any one of the following three events: (a) an increase by at least 0.25 in the Health Assessment Questionnaire II (HAQ II, a measure of disability from joint pain) score, (b) an increase in patient reported severity of joint and/or muscle pain, or (c) discontinuation from trial prior to 24 weeks specifically because of problems with musculoskeletal symptoms.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DRUG Letrozole 2.5mg
- DIETARY_SUPPLEMENT High Dose Vitamin D
- DIETARY_SUPPLEMENT Standard Dose Vitamin D3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
What the finished NCT00867217 record still lists
NCT00867217 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00867217 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00867217 about?
NCT00867217 is a clinical study titled "Vitamin D3 for Aromatase Inhibitor Induced Arthralgias". The primary purpose is to determine if high dose vitamin D3 reduces the incidence of musculoskeletal symptoms associated with the aromatase inhibitor letrozole in women with early stage breast cancer and low serum vitamin D levels.
What is the current status of trial NCT00867217?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2009-03. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00867217?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Letrozole 2.5mg (DRUG), High Dose Vitamin D (DIETARY_SUPPLEMENT), Standard Dose Vitamin D3 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00867217?
This trial is sponsored by Qamar Khan, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00867217's enrollment target sits among peer trials
160 422nd of 2000 higher than 1,559 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia